Science, Complicated Pharmacology, Patient Relationships Drew Alan Moss, M.D., to Crohn’s and Colitis
The new chief scientific officer of the Crohn’s and Colitis Foundation talked about what motivated him to pursue a career researching and taking care of Crohn’s and colitis patients.
First of five parts
In an era of U.S. healthcare that can make for fleeting and fragmented relationships between patients and clinicians, Alan Moss, M.D., has had different experience, sometimes seeing patients over many years and different stages of their lives.
“I have had patients who were in high school, then they’re in college, and (then) they’re trying to carve out a career, they’re getting pregnant. And all those things bring up a whole new batch of questions,” Moss said in a recent wide-ranging interview with Managed Healthcare Executive.
The Crohn’s and Colitis Foundation announced on Sept. 25 that Moss had been named the organization’s chief scientific officer. Moss is also the director of the Crohn’s & Colitis Program at Boston Medical Center. Prior to Boston Medical Center, he conducted research and took care of patients at Beth Israel Deaconess Medical Center, which is also in Boston.
In addition to the enduring patient relationship, Moss said he was draw to a career in inflammatory bowel disease care and research by complexities of the scientific understanding of Crohn’s disease and ulcerative colitis and the pharmacology of the treatments.
In this video segment of his conversation with MHE, Moss also discusses the research, education and advocacy aspects of his new job at the Crohn’s and Colitis Foundation.
Entyvio Associated With Lowest Risk of Adverse Events in Patients with UC, Study Finds
October 2nd 2024Treatment with Entyvio (vedolizumab), an integrin receptor antagonist, followed by Humira (adalimumab), a tumor necrosis factor blocker, resulted in the lowest overall incidence of adverse events, according to an industry-sponsored study.
Read More
The News About IBD Among Historically Marginalized People Is Not Good
September 19th 2024Results of a survey show that Black/Indigenous/People of Color or Hispanic patients with Crohn's disease or ulcerative colitis were more likely to report poor symptom control and greater difficulty accessing care from specialists and twice as likely to have an IBD-related emergency department visit compared with White non-Hispanic patients.
Read More
